Selected research
Market Analysis & Forecast
Global Pneumococcal Bacteria Vaccine Market Analysis and Forecast 2026-2032
Market perspective
The global Pneumococcal Bacteria Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Pneumococcal Bacteria Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Pneumococcal Bacteria Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Pneumococcal Bacteria Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Pneumococcal Bacteria Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global manufacturers of Pneumococcal Bacteria Vaccine include Sanofi, Merck, Pfizer, GSK, Walvax and Sinopharm, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Pneumococcal Bacteria Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Pneumococcal Bacteria Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Pneumococcal Bacteria Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Pneumococcal Bacteria Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Pneumococcal Bacteria Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Pneumococcal Bacteria Vaccine sales, projected growth trends, production technology, application and end-user industry.
Pneumococcal Bacteria Vaccine Segment by Company
Sanofi
Merck
Pfizer
GSK
Walvax
Sinopharm
Pneumococcal Bacteria Vaccine Segment by Type
PPSV 23
PCV 13
PCV 10
Pneumococcal Bacteria Vaccine Segment by Application
Infant
Children
Adult
Pneumococcal Bacteria Vaccine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pneumococcal Bacteria Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pneumococcal Bacteria Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pneumococcal Bacteria Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Sales (consumption), revenue of Pneumococcal Bacteria Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 4: Detailed analysis of Pneumococcal Bacteria Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pneumococcal Bacteria Vaccine sales, revenue, price, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.
Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.
Chapter 10: China type, by application, sales, and revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.
Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 14: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- PPSV 23
- PCV 13
- PCV 10
Applications
- Infant
- Children
- Adult
Companies covered
- Sanofi
- Merck
- Pfizer
- GSK
- Walvax
- Sinopharm
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Pneumococcal Bacteria Vaccine Market by Type
- 1.2.1 Global Pneumococcal Bacteria Vaccine Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 PPSV 23
- 1.2.3 PCV 13
- 1.2.4 PCV 10
- 1.3 Pneumococcal Bacteria Vaccine Market by Application
- 1.3.1 Global Pneumococcal Bacteria Vaccine Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Infant
- 1.3.3 Children
- 1.3.4 Adult
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Pneumococcal Bacteria Vaccine Market Dynamics
- 2.1 Pneumococcal Bacteria Vaccine Industry Trends
- 2.2 Pneumococcal Bacteria Vaccine Industry Drivers
- 2.3 Pneumococcal Bacteria Vaccine Industry Opportunities and Challenges
- 2.4 Pneumococcal Bacteria Vaccine Industry Restraints
3 Global Market Growth Prospects
- 3.1 Global Pneumococcal Bacteria Vaccine Revenue Estimates and Forecasts (2021-2032)
- 3.2 Global Pneumococcal Bacteria Vaccine Revenue by Region
- 3.2.1 Global Pneumococcal Bacteria Vaccine Revenue by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Pneumococcal Bacteria Vaccine Revenue by Region (2021-2026)
- 3.2.3 Global Pneumococcal Bacteria Vaccine Revenue by Region (2027-2032)
- 3.2.4 Global Pneumococcal Bacteria Vaccine Revenue Market Share by Region (2021-2032)
- 3.3 Global Pneumococcal Bacteria Vaccine Sales Estimates and Forecasts 2021-2032
- 3.4 Global Pneumococcal Bacteria Vaccine Sales by Region
- 3.4.1 Global Pneumococcal Bacteria Vaccine Sales by Region: 2021 VS 2025 VS 2032
- 3.4.2 Global Pneumococcal Bacteria Vaccine Sales by Region (2021-2026)
- 3.4.3 Global Pneumococcal Bacteria Vaccine Sales by Region (2027-2032)
- 3.4.4 Global Pneumococcal Bacteria Vaccine Sales Market Share by Region (2021-2032)
- 3.5 US & Canada & Mexico
- 3.6 Europe
- 3.7 China
- 3.8 Asia (Excluding China)
- 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
- 4.1 Global Pneumococcal Bacteria Vaccine Revenue by Manufacturers
- 4.1.1 Global Pneumococcal Bacteria Vaccine Revenue by Manufacturers (2021-2026)
- 4.1.2 Global Pneumococcal Bacteria Vaccine Revenue Market Share by Manufacturers (2021-2026)
- 4.1.3 Global Pneumococcal Bacteria Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Pneumococcal Bacteria Vaccine Sales by Manufacturers
- 4.2.1 Global Pneumococcal Bacteria Vaccine Sales by Manufacturers (2021-2026)
- 4.2.2 Global Pneumococcal Bacteria Vaccine Sales Market Share by Manufacturers (2021-2026)
- 4.2.3 Global Pneumococcal Bacteria Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
- 4.3 Global Pneumococcal Bacteria Vaccine Sales Price by Manufacturers (2021-2026)
- 4.4 Global Pneumococcal Bacteria Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
- 4.5 Global Pneumococcal Bacteria Vaccine Key Manufacturers Manufacturing Sites & Headquarters
- 4.6 Global Pneumococcal Bacteria Vaccine Manufacturers, Product Type & Application
- 4.7 Global Pneumococcal Bacteria Vaccine Manufacturers' Establishment Date
- 4.8 Market Competitive Analysis
- 4.8.1 Global Pneumococcal Bacteria Vaccine Market CR5 and HHI
- 4.8.2 2025 Pneumococcal Bacteria Vaccine Tier 1, Tier 2, and Tier 3
5 Pneumococcal Bacteria Vaccine Market by Type
- 5.1 Global Pneumococcal Bacteria Vaccine Revenue by Type
- 5.1.1 Global Pneumococcal Bacteria Vaccine Revenue by Type (2021 VS 2025 VS 2032)
- 5.1.2 Global Pneumococcal Bacteria Vaccine Revenue by Type (2021-2032) & (US$ Million)
- 5.1.3 Global Pneumococcal Bacteria Vaccine Revenue Market Share by Type (2021-2032)
- 5.2 Global Pneumococcal Bacteria Vaccine Sales by Type
- 5.2.1 Global Pneumococcal Bacteria Vaccine Sales by Type (2021 VS 2025 VS 2032)
- 5.2.2 Global Pneumococcal Bacteria Vaccine Sales by Type (2021-2032) & (K Doses)
- 5.2.3 Global Pneumococcal Bacteria Vaccine Sales Market Share by Type (2021-2032)
- 5.3 Global Pneumococcal Bacteria Vaccine Price by Type
6 Pneumococcal Bacteria Vaccine Market by Application
- 6.1 Global Pneumococcal Bacteria Vaccine Revenue by Application
- 6.1.1 Global Pneumococcal Bacteria Vaccine Revenue by Application (2021 VS 2025 VS 2032)
- 6.1.2 Global Pneumococcal Bacteria Vaccine Revenue by Application (2021-2032) & (US$ Million)
- 6.1.3 Global Pneumococcal Bacteria Vaccine Revenue Market Share by Application (2021-2032)
- 6.2 Global Pneumococcal Bacteria Vaccine Sales by Application
- 6.2.1 Global Pneumococcal Bacteria Vaccine Sales by Application (2021 VS 2025 VS 2032)
- 6.2.2 Global Pneumococcal Bacteria Vaccine Sales by Application (2021-2032) & (K Doses)
- 6.2.3 Global Pneumococcal Bacteria Vaccine Sales Market Share by Application (2021-2032)
- 6.3 Global Pneumococcal Bacteria Vaccine Price by Application
7 Company Profiles
- 7.1 Sanofi
- 7.1.1 Sanofi Company Information
- 7.1.2 Sanofi Business Overview
- 7.1.3 Sanofi Pneumococcal Bacteria Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.1.4 Sanofi Pneumococcal Bacteria Vaccine Product Portfolio
- 7.1.5 Sanofi Recent Developments
- 7.2 Merck
- 7.2.1 Merck Company Information
- 7.2.2 Merck Business Overview
- 7.2.3 Merck Pneumococcal Bacteria Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.2.4 Merck Pneumococcal Bacteria Vaccine Product Portfolio
- 7.2.5 Merck Recent Developments
- 7.3 Pfizer
- 7.3.1 Pfizer Company Information
- 7.3.2 Pfizer Business Overview
- 7.3.3 Pfizer Pneumococcal Bacteria Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.3.4 Pfizer Pneumococcal Bacteria Vaccine Product Portfolio
- 7.3.5 Pfizer Recent Developments
- 7.4 GSK
- 7.4.1 GSK Company Information
- 7.4.2 GSK Business Overview
- 7.4.3 GSK Pneumococcal Bacteria Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.4.4 GSK Pneumococcal Bacteria Vaccine Product Portfolio
- 7.4.5 GSK Recent Developments
- 7.5 Walvax
- 7.5.1 Walvax Company Information
- 7.5.2 Walvax Business Overview
- 7.5.3 Walvax Pneumococcal Bacteria Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.5.4 Walvax Pneumococcal Bacteria Vaccine Product Portfolio
- 7.5.5 Walvax Recent Developments
- 7.6 Sinopharm
- 7.6.1 Sinopharm Company Information
- 7.6.2 Sinopharm Business Overview
- 7.6.3 Sinopharm Pneumococcal Bacteria Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
- 7.6.4 Sinopharm Pneumococcal Bacteria Vaccine Product Portfolio
- 7.6.5 Sinopharm Recent Developments
8 North America
- 8.1 North America Pneumococcal Bacteria Vaccine Market Size by Type
- 8.1.1 North America Pneumococcal Bacteria Vaccine Revenue by Type (2021-2032)
- 8.1.2 North America Pneumococcal Bacteria Vaccine Sales by Type (2021-2032)
- 8.1.3 North America Pneumococcal Bacteria Vaccine Price by Type (2021-2032)
- 8.2 North America Pneumococcal Bacteria Vaccine Market Size by Application
- 8.2.1 North America Pneumococcal Bacteria Vaccine Revenue by Application (2021-2032)
- 8.2.2 North America Pneumococcal Bacteria Vaccine Sales by Application (2021-2032)
- 8.2.3 North America Pneumococcal Bacteria Vaccine Price by Application (2021-2032)
- 8.3 North America Pneumococcal Bacteria Vaccine Market Size by Country
- 8.3.1 North America Pneumococcal Bacteria Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 8.3.2 North America Pneumococcal Bacteria Vaccine Sales by Country (2021 VS 2025 VS 2032)
- 8.3.3 North America Pneumococcal Bacteria Vaccine Price by Country (2021-2032)
- 8.3.4 United States
- 8.3.5 Canada
9 Europe
- 9.1 Europe Pneumococcal Bacteria Vaccine Market Size by Type
- 9.1.1 Europe Pneumococcal Bacteria Vaccine Revenue by Type (2021-2032)
- 9.1.2 Europe Pneumococcal Bacteria Vaccine Sales by Type (2021-2032)
- 9.1.3 Europe Pneumococcal Bacteria Vaccine Price by Type (2021-2032)
- 9.2 Europe Pneumococcal Bacteria Vaccine Market Size by Application
- 9.2.1 Europe Pneumococcal Bacteria Vaccine Revenue by Application (2021-2032)
- 9.2.2 Europe Pneumococcal Bacteria Vaccine Sales by Application (2021-2032)
- 9.2.3 Europe Pneumococcal Bacteria Vaccine Price by Application (2021-2032)
- 9.3 Europe Pneumococcal Bacteria Vaccine Market Size by Country
- 9.3.1 Europe Pneumococcal Bacteria Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 9.3.2 Europe Pneumococcal Bacteria Vaccine Sales by Country (2021 VS 2025 VS 2032)
- 9.3.3 Europe Pneumococcal Bacteria Vaccine Price by Country (2021-2032)
- 9.3.4 Germany
- 9.3.5 France
- 9.3.6 U.K.
- 9.3.7 Italy
- 9.3.8 Netherlands
- 9.3.9 Nordic Countries
10 China
- 10.1 China Pneumococcal Bacteria Vaccine Market Size by Type
- 10.1.1 China Pneumococcal Bacteria Vaccine Revenue by Type (2021-2032)
- 10.1.2 China Pneumococcal Bacteria Vaccine Sales by Type (2021-2032)
- 10.1.3 China Pneumococcal Bacteria Vaccine Price by Type (2021-2032)
- 10.2 China Pneumococcal Bacteria Vaccine Market Size by Application
- 10.2.1 China Pneumococcal Bacteria Vaccine Revenue by Application (2021-2032)
- 10.2.2 China Pneumococcal Bacteria Vaccine Sales by Application (2021-2032)
- 10.2.3 China Pneumococcal Bacteria Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Pneumococcal Bacteria Vaccine Market Size by Type
- 11.1.1 Asia Pneumococcal Bacteria Vaccine Revenue by Type (2021-2032)
- 11.1.2 Asia Pneumococcal Bacteria Vaccine Sales by Type (2021-2032)
- 11.1.3 Asia Pneumococcal Bacteria Vaccine Price by Type (2021-2032)
- 11.2 Asia Pneumococcal Bacteria Vaccine Market Size by Application
- 11.2.1 Asia Pneumococcal Bacteria Vaccine Revenue by Application (2021-2032)
- 11.2.2 Asia Pneumococcal Bacteria Vaccine Sales by Application (2021-2032)
- 11.2.3 Asia Pneumococcal Bacteria Vaccine Price by Application (2021-2032)
- 11.3 Asia Pneumococcal Bacteria Vaccine Market Size by Country
- 11.3.1 Asia Pneumococcal Bacteria Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 11.3.2 Asia Pneumococcal Bacteria Vaccine Sales by Country (2021 VS 2025 VS 2032)
- 11.3.3 Asia Pneumococcal Bacteria Vaccine Price by Country (2021-2032)
- 11.3.4 Japan
- 11.3.5 South Korea
- 11.3.6 India
- 11.3.7 Australia
- 11.3.8 Taiwan
- 11.3.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Pneumococcal Bacteria Vaccine Market Size by Type
- 12.1.1 SAMEA Pneumococcal Bacteria Vaccine Revenue by Type (2021-2032)
- 12.1.2 SAMEA Pneumococcal Bacteria Vaccine Sales by Type (2021-2032)
- 12.1.3 SAMEA Pneumococcal Bacteria Vaccine Price by Type (2021-2032)
- 12.2 SAMEA Pneumococcal Bacteria Vaccine Market Size by Application
- 12.2.1 SAMEA Pneumococcal Bacteria Vaccine Revenue by Application (2021-2032)
- 12.2.2 SAMEA Pneumococcal Bacteria Vaccine Sales by Application (2021-2032)
- 12.2.3 SAMEA Pneumococcal Bacteria Vaccine Price by Application (2021-2032)
- 12.3 SAMEA Pneumococcal Bacteria Vaccine Market Size by Country
- 12.3.1 SAMEA Pneumococcal Bacteria Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
- 12.3.2 SAMEA Pneumococcal Bacteria Vaccine Sales by Country (2021 VS 2025 VS 2032)
- 12.3.3 SAMEA Pneumococcal Bacteria Vaccine Price by Country (2021-2032)
- 12.3.4 Brazil
- 12.3.5 Argentina
- 12.3.6 Chile
- 12.3.7 Colombia
- 12.3.8 Peru
- 12.3.9 Saudi Arabia
- 12.3.10 Israel
- 12.3.11 UAE
- 12.3.12 Turkey
- 12.3.13 Iran
- 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
- 13.1 Pneumococcal Bacteria Vaccine Value Chain Analysis
- 13.1.1 Pneumococcal Bacteria Vaccine Key Raw Materials
- 13.1.2 Raw Materials Key Suppliers
- 13.1.3 Manufacturing Cost Structure
- 13.1.4 Pneumococcal Bacteria Vaccine Production Mode & Process
- 13.2 Pneumococcal Bacteria Vaccine Sales Channels Analysis
- 13.2.1 Direct Comparison with Distribution Share
- 13.2.2 Pneumococcal Bacteria Vaccine Distributors
- 13.2.3 Pneumococcal Bacteria Vaccine Customers
14 Concluding Insights
15 Appendix
- 15.1 Reasons for Doing This Study
- 15.2 Research Methodology
- 15.3 Research Process
- 15.4 Authors List of This Report
- 15.5 Data Source
- 15.5.1 Secondary Sources
- 15.5.2 Primary Sources
- 15.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst